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Summary: In order to elucidate the question of free radical involvement in acute porphyric crisis, antioxidants were
administered to two acute intermittent porphyria patients with long-standing recurrent attacks. Clinical condition and
urinary excretion of porphyrins and porphyrin precursors were monitored before, during and after an eight week
therapy with daily doses of vitamin E, -carotene, ascorbic acid, selenium, vitamin Q, acetylcysteine, mannitol and
carnitine. Blood cell trace element profiles were followed.
The administration of the compound antioxidant formula was found not to further impair the clinical or biochemical
conditions of the patients but the incidence of the recurrent crises or the severity of the symptoms were not
positively affected. Aberrant blood cell trace element profiles with increased granulocyte manganese were normal-
ized during treatment, on cessation of the therapy again resuming the abnormal pretreatment patterns, which may
suggest an origin in oxidative stress. No correlation was observed between the concentration of granulocyte manga-
nese and the excretion of 5-aminolaevulinic acid. Indications for participation of this porphyrin precursor in a
radical generating process leading to generalized mitochondrial Superoxide dismutase induction, as conceivably
signalled by increased intracellular manganese, were thus not obtained.
The failure to note a clinical response to antioxidant therapy may be due to factors dependent upon dosage of, or
interaction between, the antioxidant compounds given, or on restricted bioavailability of the antioxidants at critical
anatomical sites, and does not per se invalidate the model of acute porphyria as a hyperoxidative condition.
Introduction in hereditary tyrosinaemia and lead intoxication where
Acute intermittent porphyria is a hereditary disorder of the excretion in ™&M* also Ρ^11ε1δ the severitv of
haem metabolism. The clinical expression is dominated the neuropsychiatric symptoms. In the search for an ex-
by neurologic disturbances and is strongly dependent on Planation for P01^0 neur°Pa% interest has therefore
exposition of the patient to external agents and hormonal focused on thls m*abolite. Under the assumption that it
f . ~u 1 1 U 1 Λ · f Λ · * *· may be a causative factor in acute porphyria a numberfactors. The molecular background is found in mutations J v v J
in the gene encoding for porphobilinogen deaminase of hyPotheses have been advanced <2)· None of these
(EC 4.3.1.8), i. e. the enzyme catalyzing the third dedi- has ** been venfied and the 1uestion of the Path°genic
cated step in haem synthesis. The resulting decrease in significance of 5-aminolaevulinate is still open. In the
catalytic capacity gives rise to a bottleneck in the haem Past few years rt has' however' been demonstrated that
synthetic chain. Increased traffic through the pathway, 5-aminolaevulinic acid after enolization and subsequent
induced e. g. by acute demands for haem, may overload iron catalyzed oxidation ParticiPates in the formation of
the porphobilinogen deaminase step and result in defi- reactive ox^en sPecies' and that * may act as a Prooxi-
cient clearing of the porphyrin precursors 5-aminolae- *"* in vitro as wdl as in vivo <for referen'es see De-
vulinate and porphobilinogen (1). Although accumula- masi et aL <3»' *&* of oxidative ίη^ in rat brain
tion of 5-aminolaevulinate, as evidenced by increased submitted to treetment with 5-aminolaevulinate point to
urinary excretion of the compound, is also noted in some thls *το^^ of the comPound as one Possible «usative
asymptomatic carriers, it is invariably present in the factor in the development of neuropathy in acute por-
symptomatic phase of the disease. The same is the case ***** <4)' Further' in a recent work * has been found
that the concentration of granulocyte manganese exhib-
- its a 4-fold increase in carriers of acute intermittent por-
') This work was supported by grants from the Karolinska Insti- Phvria· ™s has tentatively been inteφreted as due to
tute. generalized induction of the manganese-based enzyme
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mitochondrial Superoxide dismutase, conceivably in re-
sponse to augmented generation of free radical species
by 5-aminolaevulinate produced in surplus (5).
The theory of acute porphyria as a hyperoxidative condi-
tion is the incitement for the present study. An attempt
has thus been made to break long-standing chains of
recurrent porphyric attacks in two patients with acute
intermittent porphyria by administration of antioxidants.
Materials and Methods
Design of the study
Two adult carriers of different mutations for acute intermittent por-
phyria with recurrent porphyric attacks were treated for about eight
weeks with antioxidants. They were followed through time with
regard to clinical condition, porphyrin and porphyrin precursor
excretion and granulocyte, erythrocyte and platelet trace element
profiles. Informed consent from the patients was obtained.
Patients
Patient F is a 41-year-old female with acute intermittent porphyria.
Her first porphyric crisis occurred at the age of 22 and was precipi-
tated on start of use of oral contraceptives. Since then she has
had attacks yearly, characterized by increased porphyrin precursor
excretion, vomiting, abdominal pain, depression and occasional pa-
ralyses and hallucinations. During the last three years she has had
monthly attacks in a cyclic premenstrual pattern and has been sub-
jected to about forty instances of glucose and haemarginate therapy.
During the study her menstrual periods became irregular and fi-
nally stopped altogether, and the porphyric attacks recurred every
other week.
Patient Mis a 43-year-old male with acute intermittent porphyria.
After intake of disulphiram (Antabus®), at the age of 37, he devel-
oped his first porphyric attack, which was accompanied by severe
abdominal pains, tetraplegia, respiratory insufficiency and
psychotic behaviour. Since then, he has had frequent attacks
marked by abdominal pain, during the last year approximately ev-
ery other week. In all, he has received glucose and haemarginate
infusions about sixty times.
Diagnostic procedures
In both patients the diagnosis of acute porphyria was suggested by
a family history of acute porphyria and by the periodic recurrence
of neuropsychiatric symptoms accompanied by increased urinary
levels of porphobilinogen and 5-aminolaevulinic acid.
In the case of the female patient (F), the diagnosis of acute in-
termittent porphyria was assessed by the findings of low erythro-
cyte porphobilinogen deaminase activity, and a 198 Trp —> stop
mutation in the porphobilinogen deaminase gene giving rise to a
CRIM-negative condition previously shown to be associated with
acute intermittent porphyria (6). The porphobilinogen deaminase
gene exon 1, 33 G —> T mutation assessed in patient M, gives rise
to a partial deficiency of the enzyme recognized only in non-eryth-
ropoietic cells. In this patient, erythrocyte porphobilinogen deami-
nase activity thus was within the normal range of values, and the
diagnosis of acute intermittent porphyria was based on the previous
(7) demonstration of an association between the mutation in quesr
tion and this form of acute porphyria.
Antioxidant administration
The following tablets/capsules were given.
Oxigard (AGO, Sweden) contains (one tablet) D-a-tocopherol ace-
tate 50 mg, ascorbic acid 90 mg, -carotene 9 mg and sodium sele-
nite 60 μg.
Bio-Antioxidant® (Pharma Nord, Stockhohn, Sweden) contains
(one tablet) α-tocopherol acetate 97 mg, ascorbic acid 200 mg, -
carotene 7.5 mg, vitamin A 250 μg, selenium (organic) 60 μg, vita-
min B6 25 mg, vitamin BI 5 mg, niacin 5 mg, niacin amide 10 mg,
pantothenic acid 7.5 mg, zinc (organic) 7.5 mg, manganese (or-
ganic) 2 mg, copper (organic) 1 mg, vitamin B2 5 mg, vitamin B12
4.5 μg, folic acid 50 μg, biotin 100 μg, vitamin D 2.5 μg and mag-
nesium 50 mg.
C-Vitamin (AGO Stockholm, Sweden) contains (one tablet) 500 mg
ascorbic acid.
Bio-Quinon (Pharma Nord, Stockholm, Sweden) contains (one cap-
sule) 2,3-dimethoxy-5-methyl-6-decaprenyl-l,4-benzoquinone (vi-
tamin Q) 30 mg.
Acetyl-Cystein (NM Pharma, Stockholm, Sweden) contains (one
tablet) acetylcysteine 200 mg and mannitol 250 mg.
Carnitene® (Sigma-Tau) contains (one tablet) carnitine 1 g.
Administration of the tablets started on the second day in the
asymptomatic phase after a porphyric attack. The different tablets/
capsules were introduced during a 15-day-period in a day to day
sequential manner, starting with Oxigard and C-vitamin days 1—3
and followed by Bio-Quinon, Acetyl-Cysteine and Carnitene® days
4, 6 and 9, respectively. After a period of 16 days (patient M) and
32 days (patient F), Oxigard was switched to Bio-Antioxidant. All
the tablets/capsules were given in stepwise increased daily dosages.
The final doses of antioxidants were (Bio-Antioxidant period
within brackets): a-tocopherol 100 mg/day (194 mg/day); ascorbic
acid 2.18g/day (2.40 g/day) and -carotene 18 mg/day (15 mg/
day). The dose of selenium was 120 μg/day; ubiquinol 90 mg/day;
acetylcysteine 400 mg/day; mannitol 500 mg/day and carnitine
1.5 g/day. Vitamin C was taken in four daily doses (morning,
lunch, afternoon, evening); Bio-Quinon and Carnitene in three
(morning, afternoon, evening); and Oxigard, Acetyl-Cysteine and
Bio-Antioxidant in two (morning and evening).
Analytical methods
Porphobilinogen and 5-aminolaevulinic acid were quantitated in
urine by the method of Mauzerall & Granick (8), after separation
by ion exchange chromatography, as described by Davis & Andel-
man (9). Urinary porphyrins were isolated by anion exchange chro-
matography and quantitated by spectrophotometry (10). Concentra-
tions of trace elements in erythrocytes, granulocytes and platelets
were determined by the technique of particle-induced X-ray emis-
sion, using the Scanning Light Ion Microscope in Uppsala, Sweden
(Slim-Up). A complete description of the microscope and its per-
formance characteristics are found elsewhere, as are the procedures
for blood sampling, preparation of the cells from venous blood, the
sample support technique and the sampling of individual cells for
investigation (11). Trace element reference values (\ig/g dry
weight, mean ± SD; males and females) are: Granulocyte Ca 19.8
± 4.5, Mn 1.0 ± 0.5, Fe 7.3 ± 3.2 and Zn 32.8 ± 12.3; platelet
Fe 4.9 ± 1.2 and Zn 5.8 ± 2.2; erythrocyte Ca 6.8 ± 2.8 and Zn
26.5 ± 11.1.
Assessment of clinical status
The clinical conditions of the two patients were assessed by using
a self-rating scheme every 4-8 days. The symptom diary was de-
signed on the basis of previous experiences of their symptomatol-
ogy. They were thus instructed to rate the severity, on a scale of 0
to 5, of the following symptoms: nausea, vomiting, abdominal pain,
pain on breathing, other muscle pain, muscular weakness, and de-
pression.
Biochemical monitoring
At intervals of 3—6 days, related to the current clinical condition,
specimens of morning urine were collected and assayed for 5-
aminolaevulinic acid, porphobilinogen and porphyrins, the concen-
trations being related to the creatinine contents of the samples.
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Specific therapy in acute phase
Before, during and after the period of antioxidant administration
specific therapy was given in the symptomatic phase. On admission
for a porphyric crisis, haemarginate (Normosang®, Leiras Oy, Hel-
sinki, Finland) containing 23 g/1 haematin; 6 ml/24 hours, and glu-
cose, 100 g/1; 2000 ml/24 hours, were given. The infusions were
administered for periods of 3 to 6 days. As a neuroleptic, dixyrazin
(Escucos®, VCB Pharma AB, Helsingborg, Sweden) 25 mg/8
hours, was given for 4—6 days. For analgesia, morphine (Morphin
Pharmacia, Pharmacia Uppsala, Sweden) 10 g/1; 30-60 mg/24
hours was individually dosed by intra-abdominal pump. Lactulose
(Lactulos Tika, Tika, Lund, Sweden) mixture 670 g/1; 13.4 g/24 h
and sodium picosulphate (Laxoberal®, Ferring, Vanlöse, Denmark)
7.5 g/1; 5 mg/24 hours, were given from the first day against obsti-
pation.
Results
In figure 1 urinary concentrations of porphobilinogen,
5-aminolaevulinic acid and porphyrins, as well as in-
dices for clinical condition, are plotted against time. In
order to emphasize the reproduction, in the present
study, of a previous (5) observation in porphyria of
increased or upper borderline values for some of the
elements, as well as the normalization seen during anti-
oxidant therapy, the elemental concentrations are given
in percent of upper reference value ("Material and Meth-
ods"). In the case of the female patient, the menstrual
periods are indicated in the figure. Arrows show when
specific 3—4 day therapy was started because of acute
porphyric crises ("Material and Methods"). Vertical dot-
ted lines indicate the start and end of antioxidant admin-
istration.
As indicated by the biochemical and clinical variables
monitored, neither the incidence of porphyric crises, nor
the severity of the attacks were affected by the antioxi-
dants given.
Before the start of antioxidant administration, high gran-
ulocyte manganese, and high granulocyte and erythro-
cyte calcium levels, were noted in both patients. Platelet
iron values were in the upper reference range. The con-
centrations of the elements were not found to vary with
the current clinical activity of the disease and were
shown not to be dependent on the specific therapeutic
measures taken during the acute attacks ("Material and
Methods"). Nor did they follow the excretion patterns of
porphyrins or porphyrin precursors.
Within 3 weeks after the onset of antioxidant treatment,
normalization of the increased concentrations of granu-
locyte manganese, as well as of granulocyte and erythro-
cyte calcium, were noted in both patients. Other trace
elements also took part in the reaction. Granulocyte
manganese, calcium, magnesium and iron thus covari-
ated (tab. 1). The pattern also included platelet iron and
erythrocyte calcium. Zinc concentrations showed an in-
verse relation to these elements in all three types of cells
studied. The replacement of Oxigard by Bio-Antioxi-
dant ("Material and Methods") did not affect the values.
The concentrations of the blood cell trace elements about
six months after cessation of the antioxidant administra-
tion showed returns to pretreatment levels in both pa-
tients.
Discussion
The study was undertaken on the assumption that breaks
in the two patients' long standing chains of porphyric
attacks, induced by administration of antioxidants,
would point to symptomatic acute intermittent porphyria
as a hyperoxidative condition and indicate a therapeutic
option. The patients were not willing to submit to cere-
brospinal fluid sampling and since the source for damag-
ing reactive oxygen species would be 5-aminolaevulinic
acid generated within the nervous system, measurements
of plasma read-outs for oxidative damage were not at-
tempted. Aminolaevulinic acid is synthesized within the
mitochondrion and the primary site, in acute porphyria,
for an effective hydroxyl ion attack derived from this
compound most probably would be the mitochondrial
membrane within cells in the nervous system. Since
most intracellular antioxidants are compartmentalized,
the lipophilic localization of the alleged radical stress
was a prime concern in the design of the antioxidant
formula. For theoretical reasons (12), on the basis of
observations in recent experimental work (13) and on
the, possibly erroneous (vide infra), assumption that an-
tioxidant administration under no circumstances could
do the porphyric patient any harm, a compound thera-
peutic formula was designed. After a period of 16 days
and 32 days, respectively, in the two patients, it was
supplemented with vitamins of the B-complex, includ-
ing folate (14) ("Material and Methods"). There is a vast
literature regarding the mechanisms underlying the ac-
tions of the antioxidants given, and the antioxidant prop-
erties of analogues of vitamins C and E, carotenoids,
flavonoids, coenzyme Q, sulphydryl compounds and se-
lenium are well documented in biological systems (15),
although not so much in therapeutic use (12, 15). Since
no reports are available on the substances administered
with regard to porphyrinogenicity, the agents were cau-
tiously introduced, and under close clinical and bio-
chemical surveillance of the patients.
As seen in figure 1, the activity of the porphyric disease
in the two patients was reflected in their porphyrin pre-
cursor excretions. In the female patient, the attacks re-
curred in periods of 14 days and showed no temporal
connection with her menstrual cycle. The porphyric cri-
ses in the male patient took place at 10—15 day in-
tervals. The cyclic patterns of the attacks had been virtu-
ally the same for several months before the start of the
trial, and may reflect therapeutic rebounds connected
with recurrent inductions of haem oxygenase in re-
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sponse to the repeated haem infusions. Within two
weeks after the start of antioxidant therapy both patients
reported feelings of increased vigor and well-being. Nei-
ther their clinical condition, nor their porphyrin precur-
sor excretion indicated exacerbations of their porphyric
states that could be attributed to the action of substances
in the antioxidant formula given. Even in extremely vul-
nerable porphyric individuals such as the two patients
participating in the present study, compound antioxidant
therapies of the kinds used thus seem to be without
harmful porphyric side-effects.
As previously (5) observed in other individuals carrying
the porphobilinogen deaminase gene 198 Trp —* stop
mutation, the female patient before antioxidant treat-
ment had increased levels of granulocyte manganese, as
well as of granulocyte and erythrocyte calcium. This
Patient F Start of
antioxidant
therapy
I
PIo.^^ t
20 25 30 35 40 45 50 55 60 65 70 75
Time [d]
Clinical
condition
Menstruations
Glucose/
haematin
therapy
Fig. 1 Clinical conditions, excretions of 5-aminolaevulinic acid,
porphobilinogen and porphyrins, and trace element concentra-
tions in granulocytes, platelets and erythrocytes, in the two pa-
tients, before, during and after administration of an antioxidant
formula.
A female (patient F) and a male (patient M) acute intermittent
porphyria gene carrier, with recurrent acute attacks, were subjected
to an approximately eight week treatment with a compound for-
mula of antioxidants and vitamins ("Material and Methods").
Vertical dotted lines indicate start and end of antioxidant admin-
istration. Arrows indicate instances of specific therapy during
porphyric crises ("Material and Methods"). In the case of the fe-
male patient shaded boxes indicate periods of menstruation.
The trace elements are represented in the figure by the following
symbols:
Ca (*), Mn (o), Fe (>), Zn (D). Trace element intracellular concen-
trations are given in percent of upper reference values (Mean
± SD; "Material and Methods").
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pattern was also found in the male patient, who is a
carrier of the "Finnish type" exon l, 33G —» T porpho-
bilinogen deaminase gene mutation, demonstrating that
this trace element aberration is not coupled to only one
of the several mutations producing acute intermittent
porphyria. The increase in manganese in granulocytes, a
cell type with very active haem synthesis, in a previous
work was tentatively interpreted as a marker for a gener-
alized induction of the manganese-associated enzyme
mitochondrial dismutase, conceivably due to augmented
generation of the Superoxide anion radical produced by
action of ferrous iron on 5-aminolaevulinic acid (5). On
days 14 (patient M) and 23 (patient F), respectively, af-
ter initiation of the antioxidant therapy, the increased
concentrations of granulocyte manganese and calcium,
as well as of platelet iron and erythrocyte calcium,
showed abrupt decreases. The contents of zinc in all
three types of cells increased at the same time. The
changes in levels of these intracellular elements took
place in close concert and also affected the granulocyte
levels of magnesium and iron (fig. 1, tab. 1). There is a
remarkable congruence in the reaction patterns of the
two patients. The fact that the aberrant trace element
profile was reproducibly influenced by a therapeutic
preparation of antioxidants, and that cessation of antiox-
idant administration is followed by a reversion to pre-
treatment levels, may suggest that it had been induced
by oxidative stress. The difference in latency of the re-
sponse between the two patients could in the case be
due to differences in pretreatment antioxidant status. On
the other hand, no significant positive effects on the inci-
dence of the recurrent porphyric crises, or on the sever-
ity of the symptomatology, were noted. Assuming a hyp-
eroxidative origin for the porphyric symptomatology, the
Patient M
| GRANULOCYTES |
[% of upper
reference value]
Start of
antioxidant
therapy
| PLATELETS |
[% of upper
reference value]
| ERYTHROCVTES |
[% of upper
reference value]
0 S 10 15 20 25 30 35 4Ό
Clinical
condition
Glucose/
haematin
therapy
t ! t t
45 50 55 60 65 70 75 80 85 90 9!
Time [d]
t t t t
Fig. l (Patient M)
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Tab. 1 Blood cell trace elements responding to antioxidant ther-
apy in a male and female patient with acute intermittent porphyria.
Correlations with granulocyte manganese.
Blood cell type and element Correlation (r)
Female Male
Granulocyte
Manganese
Granulocyte
Calcium
Iron
Zinc
Magnesium
Platelet
Zinc
Iron
0.86
0.56
-0.95
0.86
-0.82
0.91
0.86
0.72
-0.88
0.92
-0.88
0.97
Erythrocyte
Calcium
Zinc
0.93
-0.82
0.83
-0.88
absence of a therapeutic effect could be due to a
failure of the administered compounds to reach neuro-
logical sites of pathophysiological significance, while
they were acting effectively in bioavailable compart-
ments such as blood. Thus, animal experimental mod-
els show that even with massive increases in dietary
vitamin E intake, it requires four weeks to achieve
significantly elevated antioxidant levels in brain paren-
chyma (16).
It may thus be that the doses of antioxidants given were
insufficient for penetration into the nervous system in
amounts to produce clinical effects. The Oxigard admin-
istration provided a dose of vitamin E corresponding to
a fivefold increase of Swedish recommendations for the
daily intake, and were in accordance with the supple-
mentary doses observed to lower the risks of coronary
heart disease and cancer (17, 18). The doses adminis-
tered should also be compared to those given in the anti-
oxidant treatment shown to have a beneficial effect in
recurrent pancreatitis (19), where the daily dose of vita-
min E was 189 mg (270 IU) and where -carotene 5.4
mg (900 IU), vitamin C 0.54 g, organic selenium 600
μg and methionine 2 g, were given in addition. It is note-
worthy that the contents of vitamin E, -carotene and
selenium in that formula were considerably higher than
those used in the present study. Thus it cannot be ex-
cluded that a therapeutic effect would have been attained
by use of higher doses. Concerning other antioxidants
and other disease states, no controlled therapeutic trials
have been conducted that can serve as a guide to evalu-
ate the present results.
The protective capacity of an antioxidant system most
probably depends on a fine balance between its compo-
nents. The failure of antioxidant administration to im-
prove the clinical condition in acute porphyria in the
present study could thus alternatively be dependent on
insufficient attention being paid to the strong pro-oxi-
dant nature of ferrous and cuprous ions, and that compo-
nents, i. e. ascorbate and cysteine, favoring the genera-
tion such of reduced ion species were included in high
doses in the formulas administered. This would be a cir-
cumstance of extra significance in individuals such as
the two participating in the study, probably burdened
with a high hepatic iron load resulting from the many
haem infusions received.
The two patients engaged in the trial were selected on
the basis of the fact that their regularly recurring porph-
yric crises permitted their use as own controls. Because
of difficulties enrolling individuals with such attack pat-
terns in any number, the obvious advantages of this ap-
proach are, however, partly counterbalanced by the
problem of assessing statistical significance to findings
from only two patients. Further, it is by no means given
that the studied cases, with their probable haem oxygen-
ase driven pathophysiology, are representative for more
common forms of porphyric crises, with sporadic occur-
rence and with precipitating factors perhaps acting
through other inductive mechanisms. In view of the
increasing insight into the possible role of free radicals
in porphyric illness, an expanded antioxidant study in-
cluding a larger number of patients as well as patients
with other attack patterns, and perhaps using a therapeu-
tic formula containing less reducing substances, might
be rewarding.
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